2022
Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristics
2019
Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerPD-L1 expression testingFirst-line therapyNon-small cell lung cancerPD-L1 expressionPD-L1 testingCell lung cancerLung cancerFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseCell death ligand 1 (PD-L1) expressionFDA approvalDeath ligand 1 (PD-L1) expressionReal-world practice patternsFirst-line treatmentLigand 1 expressionProportion of patientsMonths of diagnosisReal-world careMultivariable logistic regressionCommunity oncology practicesCompanion diagnostic testingExpression testingIdentifiable driver mutationsLine treatment